Around 2010, a French biotech approached European officials with a wild idea. There are these viruses called bacteriophages, the team explained, which invade bacteria, multiply, and cause the pathogens to explode. As more and more bugs were becoming resistant to antibiotics, the company wanted to use these viruses to combat unrelenting infections — and proposed souping up these helpful parasites with some genetic modification.

The officials were not impressed. “The feedback the company received from the authorities was that it would be extremely difficult to get approval,” explained Guy-Charles Fanneau de la Horie, CEO of Pherecydes Pharma, “the issue being the dissemination of GMOs into nature. This is very sensitive in Europe.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy